NTI 4.92% 5.8¢ neurotech international limited

Ann: NTI Receives HREC Approval for Rett Syndrome Clinical Trial, page-8

  1. 718 Posts.
    lightbulb Created with Sketch. 155
    Results from our initial Rett's study must be out soon.

    "Patient recruitment is expected to commence in early Q3 CY2023. The preliminary (top-line) results of the trial are anticipated in Q1 CY2024."

    "If successful, the Company will follow with a 14-week double-blind, randomised, placebo-controlled Phase II in 34 participants to determine further efficacy and safety, which will require a separate HREC submission and approval."

    GLTAH

    I believe we are cheap -- Real cheap
 
watchlist Created with Sketch. Add NTI (ASX) to my watchlist
(20min delay)
Last
5.8¢
Change
-0.003(4.92%)
Mkt cap ! $59.00M
Open High Low Value Volume
6.1¢ 6.1¢ 5.7¢ $75.08K 1.289M

Buyers (Bids)

No. Vol. Price($)
2 216913 5.9¢
 

Sellers (Offers)

Price($) Vol. No.
6.2¢ 56158 1
View Market Depth
Last trade - 15.16pm 19/06/2024 (20 minute delay) ?
NTI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.